Dr. SumanRao

Speciality

Heamatology

Biodata

 

PROFESSIONAL EXPERIENCE 

 

10/2014 - Present - Chief of Hematology, MedStar Franklin Square Medical Center

 

6/2012 - Present - Director of Thoracic Oncology, MedStar Franklin Square Medical Center

 

6/2005 - Present - Medical Oncologist/Hematologist, FRANKLIN SQUARE HOSPITAL

 

Special Interest in Breast and Lung Malignancies

 

7/2001 - 4/2005 - Medical Oncologist/ Hematologist, UNION MEMORIAL HOSPITAL

 

Director of Breast Services

 

7/1999 - 6/2001 – Assistant Professor, Hematology/Oncology, University of Texas, Southwestern Medical Center

 

7/1999 - 6/2001 – Assistant Professor, VA Hospital System,  Hematology/Oncology, Dallas, Texas

  

EDUCATION 

6/1996 - 6/1999 - Fellowship in Hematology/ Oncology, University of Texas, Southwestern Medical Center, Dallas, Texas 

6/1995 - 6/1996 - Chief Resident, St. Francis Hospital, Evanston, Illinois 

6/1992 - 6/1995 - Residency in Internal Medicine, Evanston, Illinois 

9/1988 - 9/1990 - Fellowship in Dermatology, Osmania Medical College, Hyderabad, India 

12/1985 - 12/1986 - Internship in Internal Medicine, Gandhi Hospital, Hyderabad, India 

7/1981 - 7/1986 - Medical School, Gandhi Medical College, Hyderabad, India 

6/1979 - 4/1981 - Railway Junior College, Hyderabad, India 

6/ 1969 - 4/1979 - St. Francis High School, Hyderabad, India 

 

LECTURES  

Survivorship Lectures at Union Memorial Hospital, 2011, 2012, 2013, 2014 

Grand Rounds, St. Joseph’s Hospital, Breast Cancer for the Primary Care Physician, 3/2005 

Grand Rounds, Union Memorial Hospital, Management of Breast Cancer, 8/2001 

Resident Lectures, monthly while at Union Memorial Hospital, including breast cancer management, hematologic malignancies, coagulopathic disorders, and thrombocytopenia evaluation 

Resident Lectures at Franklin Square Hospital, including anticoagulation, myeloproliferative disorders, Hodgkin’s disease, thrombocytopenia/HIT/TTP, and hypercoagulability work-up

 

MEMBERSHIPS  

American Association of Clinical Oncology 

Internal Review Board, MedStar Research Institute 

Quality Oncology Physician Initiative 

 

COMMITTEES  

Co-Chair, DHMH Survivorship Steering Committee, 2010 - 2012 

Lung Research Call Group for MedStar Hospital System 

Survivorship Committee at Franklin Square Hospital – Developed and implemented survivorship care plan and treatment summaries 

Tumor Board Coordinator - 7/2012 to Present 

 

 

Achievements

PUBLICATIONS 

 Circulating Tumor Cells:

A Useful Predictor of Treatment Efficacy in Metastatic Breast Cancer

Minetta C. Liu, Peter G. Shields, Robert D. Warren, Philip Cohen, Mary Wilkinson, Yvonne L. Ottaviano, Suman B. Rao, Jennifer Eng-Wong, Francoise Seillier-Moiseiwitsch, Anne-Michelle Noone, Claudine Isaacs JCO Nov 1 2009: 5153-5159.

 Breast Journal - submitted for publication - Increase in Mastectomies Performed on Patients in Community Settings Undergoing MRI TBJ-00032-2009.R2, AYOOLA, AYODELE, Alagarsamy, Suganthi;  

Jaboin, Jerry; Rao, Suman  

Comparison of Hormonal Receptor and HER2 New Status in Postmenopausal African-American Women vs. Caucasian Women in a Community Setting, Poster Presentation at San Antonio 2003.

 RESEARCH EXPERIENCE 

Phase III Study of Doxorubicin/Cyclophosphamide (AC) followed by Ixabepilone vs. AC followed by Paclitaxel in Patients with Triple-Negative Early-Stage Breast Cancer (TITAN) 

A Double-Blind, Randomized Phase 2b Study of Sorafenib Compared to Placebo when Administered in Combination with Chemotherapy for Patients with Locally Advanced or Metastatic Breast Cancer that has Progressed During or After Bevacizumab Therapy. (ACORN) 

a randomized, multicenter, phase iii, open-label study of the efficacy and safety of trastuzumab-mcc-dm1 vs. capecitabine + lapatinib in patients with her2-positive locally advanced or metastatic breast cancer who have received prior trastuzumab-based therapy (4370) 

a phase ii, open-label study to evaluate corrected qt interval effects of trastuzumab-mcc-dm1 (t-dm1) in patients with her2-positive locally advanced or metastatic breast cancer and to evaluate the safety and tolerability of combined t-dm1 and pertuzumab in patients with early disease progression while receiving t-dm1 alone (4688g).